The overhaul would fix the Medicare reimbursement system and align payment with CMS' current efforts to reward value-based care. For the first time, the wealthiest seniors would be asked to pay higher premiums.
As patents on some of the most lucrative medicines began to expire, many companies shifted money to rare-disease drugs, knowing that those medicines cost less to develop and will face limited competition.
The ENABLE trial, conducted in rural regions of Vermont and New Hampshire, reports a positive impact on the 1-year survival of advanced cancer patients. A parallel study, ENABLE III, reported benefits to caregivers following early introduction of palliative care in these advanced cancer patients.